| Drug Name | (Cilest (ETHINYLESTRADIOL, NORGESTIMATE |
|---|---|
| Drug Class |
Hormone
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Gynecology
|
| Risk |
The reason for the recall is that dissolution testing of norgestimate |
| Dear Healthcare provider letter DHPC |
|